CEO Christopher Hall reported Q1 2025 revenue of $20.6 million, marking a strong start to the year. He highlighted significant progress in their "Win-in-MRD" strategy, driven by demand for the company ...

Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.

Q4 2025 earnings call recap: revenue beat, MyRisk/GeneSight growth, 2026 guidance, new test launches & key risks—read now.

Leading semiconductor packaging and testing company ASE expects that fourth quarter revenue in NTD will grow 1-2% quarter-over-quarter, while semiconductor assembly and test materials (ATM) revenue is ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...

Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, ...